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drugs indicated for influenza (24%) and viral infections (excluding HIV and hepa-
titis) (18%). ConClusions: From the analysis presented here, it is clear that there 
are striking differences between infectious and parasitic disease drug approvals in 
Japan and the USA. Given the concern in Japan over the emergence of new influenza 
strains with pandemic potential, this is a great focus, constituting approximately 
a quarter of all infectious and parasitic disease drugs for the PMDA compared to 
no submissions to the FDA.
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objeCtives: In most European countries, there are usually four steps before popu-
lation access to a vaccination programme: vaccine marketing authorization by the 
European Commission, transposition of this agreement by national drug agencies, 
then recommendation and policy-decision steps on funding and implementation. 
During the recommendation step, specific to vaccines, health technology assess-
ment is often performed. Using rotavirus vaccination as an illustrative case, this 
study aims at better understanding the picture of population access, and identifying 
lessons learnt from current experience. Methods: An extensive systematic review 
of national universal rotavirus vaccination policies was conducted in 20 industrial-
ized countries (17 European & 3 major non-European). After key categories in vac-
cine evaluations were identified, comparative quantitative and qualitative analyses 
were conducted. Results: At mid-March 2014, out of the 20 countries considered, 13 
decided to include rotavirus vaccination in their childhood national vaccination pro-
gramme, 2 decided not to include it, while rotavirus decision-making process has not 
started or is underway in the remaining five countries. Published evaluations and/or 
advices on rotavirus vaccination were available in 16 countries. Quantitative analyses 
revealed that most of the countries did not take all categories into consideration, and 
some countries even assessed only two or three. ‘Burden of disease’ and ‘assessment 
of vaccine efficacy/safety’ were always taken into account, while ‘acceptability’ and 
‘implementation’ were less addressed. Qualitative analyses pointed out many differ-
ences in content and outcomes. ConClusions: Rotavirus vaccination policies across 
industrialised countries were found to be disparate, leading to unequal population 
access. Comparative analyses suggest there are different interpretations of the avail-
able evidence. This raises the need of a common decision integrated framework, using 
structured and systematic approach. This approach is not intended to substitute to 
authorities, but it could contribute to provide reproducible and structured interpreta-
tion of evidence, pave the way of the legitimacy of rotavirus vaccination programme.
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objeCtives: This study is aiming at 1) tracking expenditure on HIVAIDS, 2)how 
the government contributed to one of the MDG priority programs in Indonesia 
and its sustainability for future financing since Indonesia is one country with 
growring number of new HIVAIDS infections. Methods: Cross sectional data from 
2006-2012 was used to capture spending for HIVAIDS interventions, followed by 
policy discussion. Results: Total spending for HIVAIDS interventions increased 
from USD 56,5 miilion in 2006 to USD 87 million in 2012. The government contri-
bution has slightly increased (26.6% in 2006 and 42.36% in 2012). We found that 
75% in 2011 and 70% in 2012 of the spending were related to health. Government 
contribution for HIVAIDS as compared to total health expenditure was very lim-
ited, amounted to 0,29%, 0,27% and 0,26% in 2009, 2010 and 2011 respectively. In 
contrast, for priority programs such as HIVAIDS, external partner contribution 
has been substantial. There has been a discussion to integrate financing to the 
publicly funded program such as universal coverage that has just started recently. 
Further analysis on Opportunitistic Infection and STDs service provision for most 
at risk population was done to assess potential inclusion to the benefit package. 
Separation of the cost components to balance the role of the government and 
other sources was also assessed. Unit cost of the STDs treatment is USD 24 exclud-
ing equipment and drug. However,other country’s experience showing that the 
interventions are integrated in the universal coverage using different scheme or 
top-up. ConClusions: It should be carefully assessed the integration of HIVAIDS 
treatment to the universal coverage scheme. Stigma reduction and different price 
for private clinics need to be explored to support quality and equity. To ensure 
sustainability of the program government should play a central role to maintain 
the program, involving NGOs to engage MARP and PLHIV.
NeuRologIcal dIsoRdeRs – clinical outcomes studies
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objeCtives: This review aims to appraise the clinical and cost effectiveness of 
ivacaftor for oral administration for the treatment of cystic fibrosis (CF) in patients 
age six years and elder who have at least one G551D mutation in the CFTR (cystic 
fibrosis transmembrane conductance regulator) gene. Methods: A limited litera-
ture search was conducted of key resources, and titles and abstracts of the retrieved 
publications were reviewed. Full-text publications were evaluated for final article 
selection according to predetermined criteria (population, intervention, comparator, 
patients were found to be 100.1± 27.9 and 109 ± 15.0 .Among males, difference 
was observed in mean of HRQOL between ADR patients (99±27.92) and non ADR 
patients(107.16±14.08). Same difference were observed in mean of HRQOL among 
females which was102.18±28.68 in ADR Patients and113.69±15.95 in ADR absent 
patients. ConClusions: There is a need for a greater awareness among the health 
care professionals, regarding prevention or minimization of occurrence of ADRs by 
more frequent interventions by physicians, thus improving medication adherence 
which leads to maximization of HRQOL in HIV patients.
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objeCtives: Multiple treatments are available for chronic hepatitis C virus (HCV) 
infection. Ethical, clinical, economic, and social barriers often prevent these patients 
from receiving the effective antiviral treatments now available. These barriers to 
care have received little attention in the literature, and yet, knowledge of the ethical 
and social justice aspects of HCV treatment can enhance the quality of care. This 
study systematically reviewed evidence on the social and lifestyle determinants of 
achieving viral eradication with antiviral therapy. Methods: A search of Medline, 
Embase, and Cochrane databases (between 2004 and January 2014) was conducted 
for primary articles/conference abstracts examining social and lifestyle factors. 
Analyzed the main ethical arguments are often presented to restrict patients’ access 
to HCV treatment: the balance of risk/benefit, justice, compliance, cost-effectiveness 
and discrimination. Results: Clinical and individual level barriers to HCV treat-
ment are well evidenced. These include patient and provider concerns regarding 
co-morbidities, adherence, and side effect management. Social factors affecting 
treatment access are less well evidenced. In attempting to map these, key barri-
ers fall into the following domains: social stigma, housing, criminalisation, health 
care systems, and gender. Key facilitating factors to treatment access include: 
combination intervention approaches encompassing social as well as biomedi-
cal interventions and integrated delivery of multidisciplinary care. No trial evalu-
ated effectiveness of treatment on long-term clinical outcomes. ConClusions: 
Successful treatment of HCV infection has undeniable long-term benefits with 
respect to reducing morbidity and mortality. Perhaps the most challenging issue 
is not whether there will be medical tools to effectively manage and treat HCV 
infection, but rather whether the economic resources and societal commitment 
will be adequate to embark on an ambitious agenda to eliminate this global public 
health problem. Combination intervention approaches need to encompass systemic 
changes in policy and health care delivery. Future research needs to better delineate 
social factors affecting treatment access.
INfectIoN – Health care use & Policy studies
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objeCtives: To analyze the relationship between the change of drug mix for 
Cephalosporins and their cost increases in order to provide a reference for future 
research and government policy making on cost of antacids and anti-ulcer medica-
tions. Methods: Build a foundation based on drug DDD unit, analyze the index 
analysis system of the influence of drug mix of Cephalosporins on drug cost on 
different levels. Results: The total procurement costs of Cephalosporins for 
Guangdong province and the purchases of DDD increased by 158% and 120% respec-
tively in 2007-2011. At the same time, the price level declined significantly, the price 
index calculated by Laspeyres index decreased by 12%. ConClusions: The amount 
of drug utilization is the most important factor that caused cost increase, the 
decline of price inhibits the Cephalosporins drug price growth to a certain extent. 
Technological innovation is the motivating factor to cause the Cephalosporins drug 
price to increase.  There is a link between the level index of administration route 
and the rationality of drug use. The competition among different manufacturers is 
an important factor that affects the total expenditure of Cephalosporins.
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objeCtives: Infectious and parasitic diseases encompass some of the most deadly 
diseases including HIV, the sixth leading cause of death worldwide. The aim of this 
study was to investigate the similarities and differences between the approval of 
new drugs for the treatment of infectious and parasitic diseases in Japan and the 
USA. Methods: Drugs approved from 2004 to 2013 were identified through publi-
cally available reports on the USA Food and Drug Administration (FDA) and the 
Japanese Pharmaceuticals and Medical Devices Agency (PMDA) websites. Relevant 
drugs were defined as related to the treatment of infectious and parasitic diseases, 
according to the World Health Organisation International Classification of Diseases 
Version 2010. Results: The FDA and PMDA approved similar numbers of drugs 
indicated for infectious and parasitic diseases at 31 and 33 drugs, respectively. 
Eight HIV drugs were approved by each organisation, of which 5 were approved 
by both; each of these drugs was approved by the PMDA in the same or following 
year after FDA approval. With the exception of HIV and malarial drugs, the indi-
cations of drugs varied considerably between the FDA and PMDA. Following HIV, 
the most common infectious and parasitic drug groups for the FDA were hepatitis 
(20%), mycoses (17%) and bacterial (13%) whereas the PMDA had high incidences of 
